Evidence map›Paper›PMID 41287764›Full record

ReviewInternational journal of nanomedicine2025

Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review.

Gitishree Das, Han-Seung Shin, Jayanta Kumar Patra

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gitishree DasDepartment of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul, Goyang-si, 10326, Republic of Korea.ORCID 0000-0002-5676-0768
Han-Seung ShinDepartment of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul, Goyang-si, 10326, Republic of Korea.ORCID 0000-0001-6061-5988
Jayanta Kumar PatraDepartment of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul, Goyang-si, 10326, Republic of Korea.ORCID 0000-0003-4118-4355

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: AIDS disease, caused by HIV, is a highly prevalent disease disturbing global health and swaying economic progress and social fidelity in the world. Purpose: Eradication and cure of HIV infection has been a difficult assignment, and not many highly effective drugs and vaccines are available in the present scenario. Besides, the suboptimal adherence, toxicity, resistance to available drugs, and presence of several viral reservoirs make lifelong HIV infection treatment very challenging. Furthermore, a cure for HIV infection cannot be attained properly unless the latency issue is addressed and antiretroviral drug delivery to its specific cellular reservoir sites for an extended time is resolved. The advancement in nanotechnology could solve these issues with the formulation of advanced drugs in the nano-scale range. Currently, several nano-based architectures and formulations like nanoparticles (gold, silver, copper, and ruthenium) as nanocarriers, carbon nanotubes, liposomes, micelles, and polymer nanomaterials with superior solubility, sustained release, target specificity, long-duration delivery, and simplification of drug-dose reductions are developed which could act as effective HIV drugs/vaccine transporters in combination with available drugs and formulations. Several nano-based drug delivery approaches are suggested to target the CD4+ T cells, which are the primary target of HIV infection. While using nanoparticle-based drug delivery systems for HIV treatment, usually, three main strategies, such as the intracellular delivery of the anti-retroviral drugs by the polymeric nanoparticles, brain delivery of the anti-retroviral drugs by the polymeric nanoparticles, and use of the polymeric nanomaterials as an adjuvant for the HIV vaccines, are followed. Conclusion: Though nanotechnology offers many advantages over the conventional system of medications, it also gives rise to many side effects and challenges that need to be rectified for its better application. This review discusses the status and limits of conventional drug treatment and the recent advancements and updated strategies in nano-therapeutics for HIV treatment and cures, along with the possible mechanism of action of nano-mediated drugs, clinical translational challenges, and prospects of advanced nano-drug delivery schemes in HIV prevention and management.

Indexed as

Anti-HIV AgentsDrug Delivery SystemsHIV InfectionsNanoparticle Drug Delivery SystemNanoparticlesAnimalsHumansAnti-HIV AgentsNanoparticle Drug Delivery Systemantiretroviral drugsdrug deliveryhuman immunodeficiency virusnano carriersnano formulationsnanoparticles

Identifiers

PMID41287764
PMCPMC12640603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.